February 1, 1997Open Access

123IFP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

123IFP-CIT SPECT allows a significant discrimination between patients with Parkinson's disease and age matched controls with a one day protocol, which will be to great advantage in outpatient evaluations.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Booij et al. (Sat,) studied this question.

synapsesocial.com/papers/69dabde64a1e15904c836015 https://doi.org/https://doi.org/10.1136/jnnp.62.2.133

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [123I]β-CIT SPECT1995 · 48 citations
2Biochemical pathophysiology of Parkinson's disease.1987 · 852 citations
3Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.1993 · 360 citations
4[O-methyl-11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: Preparation, autoradiography, metabolite studies, and positron emission tomography examinations1995 · 69 citations
5Regional brain uptake and pharmacokinetics of [123I]N-ω -fluoroalkyl-2β-carboxy-3β-(4-iodophenyl) nortropane esters in baboons1995 · 41 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo